US stock · Healthcare sector · Diagnostics & Research
Company Logo

Exact Sciences Corporation

EXASNASDAQ

67.14

USD
-0.31
(-0.46%)
After Hours Market
-16.67P/E
-28Forward P/E
-0.76P/E to S&P500
11.930BMarket CAP
- -Div Yield
Upcoming Earnings
21 Feb
Shares Short
1/13/23
12.85M
Short % of Float
8.16%
Short % of Shares Outs.
7.23%
% Held by Insiders
0.89%
% Held by Institutions
88.23%
Beta
1.33
PEG Ratio
-0.20
52w. high/low
84.31/29.27
Avg. Daily Volume
2.62M
Return %
Stock
S&P 500
1 year
(11.05)
(7.99)
3 years
(29.70)
23.80
5 years
42.54
56.27
Scale: |
High
Low
4.25
0.22
3.40
0.53
9.24
3.15
9.45
4.91
12.30
7.90
14.70
6.93
29.97
10.69
32.85
6.79
22.80
4.67
63.60
13.05
82.85
37.36
123.99
60.95
144.00
35.25
159.54
71.81
84.46
29.29
72.19
45.88
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.18
0.11
(0.03)
0.15
0.13
0.08
0.07
0.06
0.02
0.43
0.97
2.30
3.72
6.68
9.87
10.31
11.45
Earnings per share
(0.49)
(0.44)
(0.36)
(0.28)
(0.29)
(0.55)
(0.88)
(0.69)
(1.25)
(1.71)
(1.63)
(0.99)
(1.43)
(0.64)
(5.61)
(3.48)
(4.10)
FCF per share
(0.47)
(0.33)
(0.29)
(0.40)
(0.35)
(0.57)
(0.75)
(0.72)
(1.16)
(1.69)
(1.42)
(1.22)
(1.80)
(2.19)
0.48
(1.39)
(2.86)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.01
0.00
0.00
0.01
0.02
0.04
0.01
0.14
0.16
0.24
0.15
0.60
1.23
1.31
0.43
0.79
1.15
Book Value per sh.
0.56
0.23
(0.09)
0.19
1.97
1.59
1.66
2.00
3.60
3.55
3.28
4.50
5.57
17.43
18.68
19.77
18.51
Comm.Shares outs.
27
27
27
33
40
53
59
67
80
92
102
116
122
131
151
171
175
Avg. annual P/E ratio
- -
(7.4)
(4.7)
(7.4)
(17.5)
(13.4)
(11.4)
(16.6)
(14.0)
(12.1)
(7.4)
(37.0)
(41.7)
(149.8)
(16.6)
(32.5)
(16.7)
P/E to S&P500
- -
(0.4)
(0.2)
(0.1)
(0.8)
(0.8)
(0.8)
(1.0)
(0.8)
(0.6)
(0.3)
(1.6)
(1.7)
(6.2)
(0.4)
(1.1)
(0.8)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
5
3
(1)
5
5
4
4
4
2
39
99
266
454
876
1,491
1,767
2,005
Operating margin
(298.3)%
(437.7)%
1,150.3%
(194.3)%
(221.3)%
(692.4)%
(1,270.3)%
(1,128.4)%
(5,591.7)%
(403.3)%
(170.1)%
(44.5)%
(35.1)%
(26.7)%
(51.5)%
(48.4)%
(35.0)%
Depreciation (m)
(3)
(2)
1
0
0
0
1
1
4
8
12
16
23
50
163
180
193
Net profit (m)
(13)
(12)
(10)
(9)
(12)
(29)
(52)
(47)
(100)
(158)
(167)
(114)
(175)
(84)
(849)
(596)
(716)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.2%
(0.1)%
68.8%
1.0%
29.3%
1.5%
Net profit margin
(271.9)%
(407.5)%
1,123.5%
(191.8)%
(216.2)%
(688.8)%
(1,266.1)%
(1,122.4)%
(5,564.4)%
(400.1)%
(168.3)%
(43.0)%
(38.5)%
(9.6)%
(56.9)%
(33.7)%
(36.0)%
Working capital (m)
15
8
0
19
89
86
97
128
274
299
303
419
1,091
320
1,623
909
625
Long-term debt (m)
- -
- -
- -
1
1
1
1
1
1
5
5
4
689
828
1,464
2,362
2,419
Equity (m)
15
6
(2)
6
80
83
99
135
289
327
335
520
681
2,288
2,823
3,388
3,109
ROIC
- -
- -
- -
- -
- -
- -
(52.1)%
(33.4)%
(34.0)%
(46.7)%
(48.2)%
(21.5)%
(10.0)%
(2.0)%
(17.6)%
(9.5)%
(12.0)%
Return on capital
(54.1)%
(81.9)%
(165.2)%
(35.4)%
(12.0)%
(29.6)%
(46.8)%
(31.7)%
(32.1)%
(43.3)%
(44.3)%
(19.1)%
(9.1)%
(5.9)%
(15.7)%
(12.4)%
(11.3)%
Return on equity
(86.3)%
(190.2)%
400.4%
(149.8)%
(14.5)%
(34.3)%
(53.2)%
(34.4)%
(34.6)%
(48.3)%
(49.9)%
(22.0)%
(25.7)%
(3.7)%
(30.1)%
(17.6)%
(23.0)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
3 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 3,198
Total assets
$ 6,307
Long-term debt
$ 2,419
Cash and equiv.
$ 235
Goodwill
$ 2,345
Retained earnings
$ (3,137)
Common stock
177
Enterprise Value
$ 14,114
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
324
1,840
1,030
Receivables
131
233
217
Inventory
62
92
105
Other
41
1,347
212
Current assets
557
2,199
1,426
Acc. Payable
26
36
68
Debt due
9
268
20
Other
202
272
430
Current liabilities
236
576
517
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
18.49%
63.09%
289.86%
Cash flow
(429.96)%
(117.17)%
(34.54)%
Earnings
(29.81)%
220.37%
113.04%
Dividends
- -
- -
- -
Book value
19.98%
77.56%
59.11%
Insider Trading
Type
Shares
Date
Condella Sarah
Sale
1,000
02/01/23
Doyle James Edward
Exempt
5,477
01/13/23
Doyle James Edward
Exempt
5,477
01/13/23
Condella Sarah
Sale
1,000
01/09/23
Coward D Scott
Award
7,780
01/03/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
348
269
408
466
1,491
2021
402
435
456
474
1,767
2022
487
522
523
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.70)
(0.57)
(1.45)
(2.89)
(5.61)
2021
(0.18)
(1.03)
(0.97)
(1.29)
(3.48)
2022
(1.04)
(0.94)
(0.84)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Mr. Kevin Conroy
Full-time employees:
6,420
City:
Madison
Address:
441 Charmany Dr
IPO:
Jan 30, 2001
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Recent News